Wiedemann B
Pharmazeutische Mikrobiologie, Universität Bonn.
Arzneimittelforschung. 1997 Oct;47(10):1165-71.
Many new antibiotics with improved pharmacodynamic and pharmacokinetic properties have been developed in the last 30 years. This development, however, went down in the last five years. With modern techniques of sequencing of the complete bacterial genum in order to find new targest, with combinatory chemistry and with the high throughput screening about one new drug per year can be developed in the future. The activity of antibiotics is diminished by the increasing number of resistant strains and by the increase of infections with naturally resistant microorganisms. The rational use of antibiotics can slow down this trend and perhaps reverse it. To reach this aim it is necessary to increase research activities in the field of pharmacodynamics in order to allow a more rational dosing. Better technology documentation and statistics in microbiological diagnostics could improve calculated chemotherapy. Furthermore we need more information about the epidemiology of resistant bacteria, at least the knowledge about receptors, mechanism of action and mechanism of resistance should be known to circumvent these obstacles in antimicrobial chemotherapy.
在过去30年里,已经研发出了许多具有改善的药效学和药代动力学特性的新型抗生素。然而,在过去五年中,这一发展有所下降。借助用于寻找新靶点的完整细菌基因组测序的现代技术、组合化学以及高通量筛选,未来每年大约可以研发出一种新药。抗生素的活性因耐药菌株数量的增加以及天然耐药微生物感染的增多而降低。合理使用抗生素可以减缓这一趋势,甚至可能使其逆转。为实现这一目标,有必要增加药效学领域的研究活动,以便实现更合理的给药。微生物诊断中更好的技术文档和统计数据可以改善化疗方案的制定。此外,我们需要更多关于耐药细菌流行病学的信息,至少应该了解受体、作用机制和耐药机制,以克服抗菌化疗中的这些障碍。